Sharon Wright
Psychiatric/Mental Health · Huntsville, ALNPI 1700094463
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.5% of the total across 402 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 13 manufacturers, the largest accounting for just 22.1% — the pattern of someone who eats at a lot of different presentations.
Across 402 payments — averaging $15.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Johnson & Johnson$847
- Otsuka America Pharmaceutical, Inc.$823
- Teva Pharmaceuticals USA, Inc.$682
- Alkermes, Inc.$647
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$545
- plus $1K from 7 others
What the payments were for
- Food & beverage$6,30298%
- Education$972%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 90 | $1,415 |
| Johnson & Johnson | 48 | $847 |
| Otsuka America Pharmaceutical, Inc. | 64 | $823 |
| Teva Pharmaceuticals USA, Inc. | 40 | $682 |
| Alkermes, Inc. | 34 | $647 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 42 | $545 |
| Neurocrine Biosciences, Inc. | 22 | $406 |
| Indivior Inc. | 26 | $399 |
| Vanda Pharmaceuticals Inc. | 16 | $263 |
| Lundbeck LLC | 8 | $146 |
| Axsome Therapeutics, Inc. | 7 | $117 |
| Sunovion Pharmaceuticals Inc. | 3 | $54 |
| E.r. Squibb & Sons, L.L.C. | 2 | $53 |
How this compares
$6,398 in reported general payments places this provider in the 85th percentile of 378 psychiatric/mental health providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega SustennaPaliperidone Palmitate | 121 | $315,778 |
| IngrezzaValbenazine Tosylate | 26 | $209,721 |
| AustedoDeutetrabenazine | 22 | $172,562 |
| Abilify MaintenaAripiprazole | 29 | $78,427 |
| VraylarCariprazine Hcl | 44 | $62,311 |
| UzedyRisperidone | 14 | $59,298 |
| Risperdal ConstaRisperidone Microspheres | 23 | $54,373 |
| TrintellixVortioxetine Hydrobromide | 51 | $35,324 |
| CaplytaLumateperone Tosylate | 20 | $32,217 |
| AristadaAripiprazole Lauroxil | 13 | $29,658 |
| LatudaLurasidone Hcl | 12 | $16,562 |
| Lurasidone Hcl | 59 | $10,665 |
| Ziprasidone Hcl | 81 | $6,066 |
| Aripiprazole | 110 | $5,496 |
| Quetiapine Fumarate | 314 | $4,184 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Sustenna, Risperdal Consta | $847 | $370,151144 claims |
| Teva Pharmaceuticals USA, Inc.Austedo, Uzedy | $682 | $231,85936 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $406 | $209,72126 claims |
| Otsuka America Pharmaceutical, Inc.Abilify Maintena | $823 | $78,42729 claims |
| AbbVieVraylar | $1,415 | $62,31144 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $545 | $32,21720 claims |
| Alkermes, Inc.Aristada | $647 | $29,65813 claims |
| Sunovion Pharmaceuticals Inc.Latuda | $54 | $16,56212 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 378 psychiatric/mental health providers in Alabama.
Other psychiatric/mental health in Huntsville
- Ian KinzerHuntsville$15K
- Narae PhulongphiaHuntsville$9K
- Josiah AldrupHuntsville$7K
- Laura GrahamMontgomery$80K
- Yuliya SpencerBirmingham$65K
- Keri BarrBay Minette$35K
- John HayesMobile$30K
- Logan ThrasherHoover$22K
- Anthony PhillipsHelena$15K
- Latisha AliHoover$15K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.